Coave Therapeutics and Théa Open Innovation sign exclusive agreement
Coave Therapeutics enters into an exclusive licensing, co-development, and commercialization agreement with Théa Pharma.
top of page
Search
- Aug 12, 2020
FDA grants fourth ODD for treatment of PDE6B gene mutation-associated retinal diseases
FDA granted 4th Orphan Drug Designation for novel gene therapy product candidate (OCU400, Ocugen Inc.) in treatment of PDE6B gene mutation.
- Apr 18, 2018
Longitudinal Clinical Follow-up and Genetic Spectrum of Patients with Rod-Cone Dystrophy associated
Compares genotype, phenotype, and structural changes in patients with rod-cone dystrophy (RCD) associated with mutations in PDE6A or PDE6B
- Oct 15, 2016
Prenylated retinal ciliopathy protein RPGR interacts with PDE6B,
Regulates ciliary localization of Joubert syndrome-associated protein INPP5E Kollu N. Rao, Wei Zhang, Linjing Li, Manisha Anand, and...
- Oct 15, 2016
Prenylated retinal ciliopathy protein RPGR interacts with PDE6B and regulates ciliary localization of Joubert syndrome-associated protein INPP5E
RPGR as a critical to cilia and suggest that trafficking of INPP5E to cilia depends upon the interaction of RPGR with PDE6B.
All Posts
bottom of page